<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Occipital nerve stimulation for the treatment of patients with medically refractory occipital neuralgia: Congress of Neurological Surgeons systematic review and evidence-based guideline.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sweet JA, Mitchell LS, Narouze S, Sharan AD, Falowski SM, Schwalb JM, Machado A, Rosenow JM, Petersen EA, Hayek SM, Arle JE, Pilitsis JG. Occipital nerve stimulation for the treatment of patients with medically refractory occipital neuralgia: Congress of Neurological Surgeons systematic review and evidence-based guideline. Neurosurgery. 2015 Sep;77(3):332â41. [23 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26125672&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The rating scheme used for strength of the evidence (&lt;strong&gt;Class I-III&lt;/strong&gt;) and the levels of recommendations (&lt;strong&gt;Level I-III&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary of Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The data from a recent systematic review of the literature supports the use of occipital nerve stimulation (ONS) as a treatment option for patients with medically refractory&amp;nbsp;occipital neuralgia (ON) (&lt;strong&gt;Level III recommendation&lt;/strong&gt;). A summary of the recommendation for the use of ONS for the treatment of ON can be found in Table 4 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for Primary Research Question&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;8%&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Economic and Decision Analyses: Developing an Economic or Decision Model&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I RCTs (and study results were homogenous&lt;sup&gt;3&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality prospective study&lt;sup&gt;4&lt;/sup&gt; (all patients were enrolled at the same point in their disease with &amp;ge;80% follow-up of enrolled patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality RCT (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prospective&lt;sup&gt;4&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Untreated controls from an RCT &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality prospective study (e.g., patients enrolled at different points in their disease or &amp;lt;80% follow-up) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Study of nonconsecutive patients; without consistently applied &quot;gold&quot; standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Analyses based on limited alternatives and costs; and poor estimates &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series&lt;sup&gt;8&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poor reference standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses with no sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;RCT = randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;A combination of results from two or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;The study was started after the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Patients identified for the study based on their outcome, called &quot;cases&quot; (e.g., failed total arthroplasty) are compared to those who did not have outcome, called &quot;controls&quot; (e.g., successful total hip arthroplasty).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Patients treated one way with no comparison group of patients treated in another way.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence on Therapeutic Effectiveness and Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence on Therapeutic Effectiveness and Levels of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I evidence: Level I recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from &amp;ge;1 well-designed, randomized, controlled clinical trials, including overviews of such trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II evidence: Level II recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from &amp;ge;1 well-designed comparative clinical studies, such as nonrandomized cohort studies, case-control studies, and other comparable studies, including less well designed randomized, controlled trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III evidence: Level III recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from case series, comparative studies with historical controls, case reports, and expert opinion, as well as significantly flawed randomized, controlled trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Occipital neuralgia (ON)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Neurological Surgery" />
      <FieldValue Value="Neurology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To systematically review the medical literature and provide recommendations for the use of occipital nerve stimulation (ONS) for the treatment of patients with medically refractory occipital neuralgia (ON).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The Task Force restricted their analysis to the use of ONS for the treatment of ON. This technique has also been used for the treatment of other disorders, most prominently migraine headaches. Given the heterogeneity of that diagnosis, they did not include it in this set of guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with medically refractory occipital neuralgia (ON)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Occipital nerve stimulation (ONS)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Change in visual analog scale (VAS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Change in short-form McGill Pain Questionnaire &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improvement in the Pain Disability Index score &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom improvement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of analgesic medication &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Literature Search&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A systematic literature search was undertaken to address the primary question: Is occipital nerve stimulation (ONS) an effective treatment for occipital neuralgia (ON)? Using the PubMed database, a search of articles published between 1966 and April 2014 was conducted using the following text word combinations: &quot;occipital nerve stimulation and occipital neuralgia&quot; or &quot;electrical stimulation and occipital neuralgia&quot; or &quot;neuromodulation and occipital neuralgia&quot; or &quot;peripheral neurostimulation and occipital neuralgia&quot; or &quot;occipital nerve stimulation and cervicogenic headache&quot; or &quot;neuromodulation and cervicogenic headache&quot; or &quot;occipital nerve stimulation and C2 headache.&quot; These searches generated lists of 50, 38, 21, 11, 11, 6, and 10 articles, respectively. Each article was reviewed by at least 2 independent reviewers to determine whether they met the qualifications for full text review. Cochrane Library was also searched with a combination of the keywords used to search PubMed (see the Supplemental Digital Content document [see the &quot;Availability of Companion Documents&quot; field]); however, no unique results were located.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force performed a secondary literature search to see whether there were interventions that predict response to ONS in ON. Using the PubMed database up to June 2014, the following text words were combined for the search: &quot;occipital nerve block and occipital nerve stimulation&quot; or &quot;occipital nerve block and occipital nerve stimulation and occipital neuralgia&quot; or &quot;occipital nerve blocks predictive of occipital nerve stimulation&quot; or &quot;response to occipital nerve stimulation and occipital neuralgia&quot; or &quot;occipital nerve block and stimulation response&quot; or &quot;occipital nerve block predictive of peripheral nerve stimulation&quot; or &quot;predictors of occipital peripheral nerve stimulation&quot; or &quot;predictors of peripheral nerve stimulation and occipital neuralgia&quot; or &quot;occipital nerve injections and occipital neuralgia&quot; or &quot;occipital nerve injection and occipital nerve stimulation.&quot; A total of 89 unique articles were found. Only 8 articles looked at an intervention in patients with ON and none of these articles included patients with ONS. Cochrane Library was also searched with a combination of the keywords used to search PubMed (see the Supplemental Digital Content document); however, no unique results were located.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Article Inclusion Criteria&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Inclusion criteria were as follows: (1) clinical series must have a minimum of 3 patients undergoing ONS for treatment of medically refractory ON, (2) clinical series must have a minimum of 2 months postoperative follow-up from ONS implantation, and (3) series that enrolled mixed patient populations were included only if they reported separate results for the target ON population. The results of the target population were the only results considered as evidence to support the recommendations. A total of 81 unique articles were found. Clinical series containing 3 or more patients with a minimum follow-up of 2 months were pooled for analysis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Of the 81 articles, 72 studies were excluded for the following reasons: 1 was an abstract only, 2 were animal studies, 4 were not in English, 11 were case reports with a single patient, 6 were meta-analyses, 17 were review articles, 30 addressed either an alternative disease process (e.g., trigeminal neuralgia or chronic migraines) or a treatment option other than ONS (e.g., occipital nerve blocks), and 1 was a mixed population of patients that did not separate the results for each population group. Ultimately, 9 original articles were selected and retrieved for analysis. These articles are listed in the Evidentiary Table (see Table 2 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A secondary analysis of the 9 selected articles was also performed in an effort to address any significant anatomic or technical considerations for ONS implantation. All of the 9 articles made at least 1 reference to an anatomic and/or technical aspect of ONS, which are also shown in Table 2 of the original guideline document.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Nine primary articles addressed the efficacy of occipital nerve stimulation (ONS) for the specific treatment of occipital neuralgia (ON) (see Table 2 in the original guideline document). All articles provided Class III Level evidence. Three articles were prospective case series without a control group and as such were graded as Class III. One article was a cohort study in which each patient served as his or her own control. However, the data were collected and reviewed retrospectively, making this Class III evidence as well. Four articles were retrospective case series, thus accounting for their classification. Finally, 1 article did not specify whether it was prospective or retrospective, but, given it was a small case series, it was also graded as Class III.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Levels of Evidence for Primary Research Question&lt;/span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;8%&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Economic and Decision Analyses: Developing an Economic or Decision Model&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I RCTs (and study results were homogenous&lt;sup&gt;3&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality prospective study&lt;sup&gt;4&lt;/sup&gt; (all patients were enrolled at the same point in their disease with &amp;ge;80% follow-up of enrolled patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality RCT (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prospective&lt;sup&gt;4&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Untreated controls from an RCT &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality prospective study (e.g., patients enrolled at different points in their disease or &amp;lt;80% follow-up) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Study of nonconsecutive patients; without consistently applied &quot;gold&quot; standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Analyses based on limited alternatives and costs; and poor estimates &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series&lt;sup&gt;8&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poor reference standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses with no sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;RCT = randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;A combination of results from two or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;The study was started after the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Patients identified for the study based on their outcome, called &quot;cases&quot; (e.g., failed total arthroplasty) are compared to those who did not have outcome, called &quot;controls&quot; (e.g., successful total hip arthroplasty).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Patients treated one way with no comparison group of patients treated in another way.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Grading Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of evidence of each article that underwent full text review was graded according to the criteria established by the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Joint Guidelines Committee (JGC). Each article was independently graded by multiple reviewers, and any conflicts between the reviewers' grading was resolved via discussion. The class of evidence (i.e., Class I, II, or III) assigned to each article was determined after review of the sample size, study design, follow-up, and outcome measures (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Guideline Task Force&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A multidisciplinary task force of volunteer neurosurgeons and pain management physicians comprised the Guidelines Task Force and were responsible for the formation of these evidence-based guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Guideline Panel Consensus&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The literature searches were performed by a single member of the group and distributed to the entire group for literature review, article selection, and the formation of the evidentiary table. Task Force subgroups were then established by topic. Information was compiled by that subgroup and then distributed to the entire group for review until a final consensus by means of group discussion, voting, and approval was achieved.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force implemented a modified structured voting technique to finalize and approve the recommendations and strength of recommendations presented in this review. If and when a disparity in opinions occurred, every effort was made to amend the guideline to adequately address each viewpoint until all members were in agreement. In the event that a unanimous decision could not be made, the question was posed to the Task Force as a whole, and the majority opinion was used. This method was agreed upon by all members of the Task Force.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Levels of Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of clinical recommendations (i.e., Level I, II, or III) was linked to the level of evidence included to support the recommendation (see the &quot;Rating Scheme for the Strength of the Recommendations field&quot;).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence on Therapeutic Effectiveness and Levels of Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence on Therapeutic Effectiveness and Levels of Recommendation&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I evidence: Level I recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from &amp;ge;1 well-designed, randomized, controlled clinical trials, including overviews of such trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II evidence: Level II recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from &amp;ge;1 well-designed comparative clinical studies, such as nonrandomized cohort studies, case-control studies, and other comparable studies, including less well designed randomized, controlled trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III evidence: Level III recommendation&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from case series, comparative studies with historical controls, case reports, and expert opinion, as well as significantly flawed randomized, controlled trials&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Practice Guideline Approval Process&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The completed systematic review was distributed to the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) for consideration of endorsement by the CNS Executive Committee and the AANS Board of Directors. JGC reviewers were permitted to critique the content and methodology used to create this systematic review. Any concerns of the JGC were addressed by the Task Force, and the document was resubmitted to the JGC for endorsement. In addition, these guidelines were independently submitted to the American Society of Regional Anesthesia and Pain Medicine and the American Interventional Headache Society for review and were approved for endorsement by these organizations. As such, support of these guidelines was also multidisciplinary in nature. Once this process was completed, the document was submitted for publication. This was editorially independent of the funding agencies of the CNS Executive Committee and the AANS/CNS Joint Pain Section Executive Committee, whose involvement occurred after the approval of the guidelines by the JGC and was limited to acceptance versus rejection of endorsement of the work.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for the recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Occipital nerve stimulation (ONS) constitutes a promising therapy for medically refractory occipital neuralgia (ON) because it is reversible with minimal side effects and has shown continued efficacy with long-term follow-up.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The major technical problem of occipital nerve stimulation (ONS) is lead migration, ranging in several prospective studies on ONS for the treatment of migraines from 13.9% to 24%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of ONS from the 9 primary articles are summarized and shown in Table 3 in the original guideline document. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The literature review and presented evidence-based guidelines were developed by a multidisciplinary group of physician volunteers. The purpose of these guidelines is to serve as an educational resource assessing the currently available scientific evidence pertaining to the use of occipital nerve stimulation (ONS) for the treatment of medically refractory occipital neuralgia (ON). The guidelines in this article are based on up-to-date information at the time of completion of this document. These guidelines are not intended to be a rigid protocol, and clinical interventions may vary according to a patient's needs. Clinical judgment should always take precedence in the treatment of patients. These guidelines are presented with the understanding that they are not meant to replace the individualized care and treatment of a specific patient by his or her physician(s). These guidelines may not be suitable in all situations or applicable to all patients with ON. Implementation of these guidelines should be done by a patient's managing physician(s) in accordance with each patients individual circumstances and clinical needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The primary limitation of this guideline is the current level of evidence available for the use of ONS specifically for the treatment of medically refractory ON. Although prospective, randomized, controlled trials and other well-designed studies demonstrating the effectiveness of ONS have been conducted, the patient populations evaluated in these studies were not specific to medically refractory ON patients. Prospective comparative studies are needed to fully determine the long-term utility of ONS for the treatment of ON. It will be difficult to conduct blinded trials of ONS because the therapy depends on the production of paresthesia detected by the patient in the painful region. The closest alternative is the use of subthreshold stimulation, but there are some who believe that even subthreshold stimulation can result in a therapeutic effect. Research also needs to be conducted into the optimal region for lead placement and the optimal lead type. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Mobile Device Resources" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sweet JA, Mitchell LS, Narouze S, Sharan AD, Falowski SM, Schwalb JM, Machado A, Rosenow JM, Petersen EA, Hayek SM, Arle JE, Pilitsis JG. Occipital nerve stimulation for the treatment of patients with medically refractory occipital neuralgia: Congress of Neurological Surgeons systematic review and evidence-based guideline. Neurosurgery. 2015 Sep;77(3):332â41. [23 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26125672&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2015 Sep" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="Congress of Neurological Surgeons - Professional Association" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Sources of Support&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This systematic review and evidence-based clinical practice guideline was funded exclusively by Congress of Neurological Surgeons (CNS) and the Joint Section on Pain of the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS), who received no funding from outside commercial sources to directly support the development of this document unless otherwise stated in this section.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Task Force&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: Jennifer A. Sweet, MD, Department of Neurological Surgery, University Hospitals Case Medical Center, Cleveland, Ohio; Laura S. Mitchell, MA, Guidelines Department, Congress of Neurological Surgeons, Schaumburg, Illinois; Samer Narouze, MD, PhD, Department of Anesthesiology and Pain Management, Western Reserve Hospital, Cuyahoga Falls, Ohio; Ashwini D. Sharan, MD, Departments of Neurosurgery and Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania; Steven M. Falowski, MD, Department of Neurosurgery, St. Luke's University Health Network, Bethlehem, Pennsylvania; Jason M. Schwalb, MD, Department of Neurosurgery, Henry Ford Medical Group, West Bloomfield, Michigan; Andre Machado, MD; Department of Neurosciences, Cleveland Clinic, Lerner Research Institute, Center for Neurological Restoration, Cleveland, Ohio; Joshua M. Rosenow, MD; Department of Neurosurgery, Northwestern University Medical School, Chicago, Illinois; Erika A. Petersen, MD, Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas; Salim M. Hayek, MD, Department of Anesthesiology, University Hospitals Case Medical Center, Cleveland, Ohio; Jeffrey E. Arle, MD, PhD, Division of Neurosurgery, Beth Israel Deaconess, Boston, Massachusetts; Julie G. Pilitsis, MD, Division of Neurosurgery, Albany Medical College, Albany, New York&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Disclosures&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Machado has ownership interest and consulting agreements with Enspire, ATI, and Cardionomics. Dr Sharan has consulting relationships with Medtronic, has received grants and honoraria from St. Jude Medical, is a Director and has ownership interest in ICP and in ICVRX. Dr Petersen is a consultant for St. Jude Medical and Medtronic. Dr Hayek is a consultant for Boston Scientific, Flowonix, and Mallinckrodt. Dr Arle is a consultant for St. Jude Medical. Dr Rosenow is a consultant for Boston Scientific and the GLG Group. Dr Schwalb has received honoraria from Medtronic. Dr Pilitsis is a consultant for and has received grants from Medtronic, St. Jude Medical, and Boston Scientific, and is a recipient of an NIH grant. Dr Falowski has research grants from and is a consultant for Medtronic and St. Jude Medical. All other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article and related to occipital nerve stimulators.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist">
      <FieldValue Value="American Association of Neurological Surgeons - Medical Specialty Society" />
      <FieldValue Value="American Interventional Headache Society - Professional Association" />
      <FieldValue Value="American Society of Regional Anesthesia and Pain Medicine - Medical Specialty Society" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available in PDF and ePUB for eBook devices from the &lt;a href=&quot;http://journals.lww.com/neurosurgery/Fulltext/2015/09000/Occipital_Nerve_Stimulation_for_the_Treatment_of.3.aspx&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Occipital nerve stimulation for the treatment of patients with medically refractory occipital neuralgia: Congress of Neurological Surgeons systematic review and evidence-based guideline. Supplemental Digital Content. 2015 Sep. 1 p. Available from the &lt;a href=&quot;http://links.lww.com/NEU/A744&quot; title=&quot;Neurosurgery Web site&quot;&gt;Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Guideline development methodology: endorsed by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint Guideline Committee. 2012 Feb. 12 p. Available from the &lt;a href=&quot;https://www.cns.org/sites/default/files/jgcguidelinedevelopmentmethodology.pdf&quot; title=&quot;Congress of Neurological Surgeons Web site&quot;&gt;Congress of Neurological Surgeons Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on November 19, 2015. The information was not verified by the guideline developer. This summary was updated by ECRI Institute on February 15, 2017 following the U.S. Food and Drug Administration advisory on general anesthetic and sedation drugs.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>